IL6 and cancer: The rationale to target trans‐signaling in disease, rather than the “classic” IL‐6 signaling mode which is dependent on the membrane‐bound IL‐6R, is based on the opposing roles of IL‐6 in either maintaining homeostatic processes (e.g., regulation of B‐cell function, the acute phase response, and hematopoiesis), or conversely, driving chronic disease states such as inflammation and cancer (Scheller et al, 2011; Mihara et al, 2012; Jones & Jenkins, 2018).